Oncopeptides AB (publ) (STO:ONCO)

Sweden · Delayed Price · Currency is SEK

1.622

-0.078 (-4.59%)

At close: Mar 2, 2026

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Biotechnology	71.12M	31.65M	35.22M	8.36M	118.30M
Biotechnology Growth	124.72%	-10.14%	321.54%	-92.94%	-
Total	71.12M	31.65M	35.22M	8.36M	118.30M
Total Growth	124.72%	-10.14%	321.54%	-92.94%	-

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Europe	71.12M	-	-	560.00K	-
Asia	-	1.13M	-	-	-
USA	-	-	24.33M	7.80M	118.30M
USA Growth	-	-	212.12%	-93.41%	-
Germany	-	17.21M	6.57M	-	-
Germany Growth	-	161.87%	-	-	-
Greece	-	5.99M	4.32M	-	-
Greece Growth	-	38.66%	-	-	-
Austria	-	1.13M	-	-	-
Spain	-	6.19M	-	-	-
Total	71.12M	31.65M	35.22M	8.36M	118.30M
Total Growth	124.72%	-10.14%	321.54%	-92.94%	-

Source: S&P Global Market Intelligence.